✦ LIBER ✦

Using Response to Primary Chemotherapy to Select Postoperative Therapy: Long-Term Results from a Prospective Phase II Trial in Locally Advanced Primary Breast Cancer

✍ Scribed by Ana Maria Gonzalez-Angulo; Ronald Walters; Kristine Broglio; Debbie K. Frye; Eric A. Strom; Richard L. Theriault; Daniel J. Booser; Vicente Valero; Aman U. Buzdar; Gabriel N. Hortobagyi

Book ID: 119934806
Publisher: CIG Media Group, LP.
Year: 2008
Tongue: English
Weight: 111 KB
Volume: 8
Category: Article
ISSN: 1526-8209
DOI: 10.3816/cbc.2008.n.063

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5174 Predictive factors of response to n

5174 Predictive factors of response to neoadjuvant 3-weekly epirubicin (EPI) plus docetaxel (DOC) chemotherapy (CT) in locally advanced breast cancer (LABC): a prospective phase II trial

✍ Strada, M.R.; Frascaroli, M.; Palumbo, R.; Bernardo, A.; Villani, L.; Scelsi, M. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Is ERBB-2 A predictive marker for respon

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

✍ P. De Crémoux; V. Diéras; V. Le Doussal; A. Vincent-Salomon; M. Tubiana-Hulin; J 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Prognostic relevance of hormone receptor

Prognostic relevance of hormone receptor and HER2 status in T4 breast cancer patients who failed to receive a pathological complete response following primary chemotherapy. Long term results from a single institution

✍ M. lonta; V. Pusceddu; B. Frau; M. Murgia; M. Barca; M. Murru; D. Guerzoni; A. C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 67 KB

1–36 The Use of Alternate, Non-Cross-Res

1–36 The Use of Alternate, Non-Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-term Results From a Prospective Randomized Trial

✍ TL, Smith 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views